CoChat

Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Atypical antipsychotic (AAP) medications that have revolutionized the treatment of mental illness have become stigmatized by metabolic side effects, including obesity and diabetes. It remains controversial whether the defects are treatment induced or disease related. Although the mechanisms underlying these metabolic defects are not understood, it is assumed that the initiating pathophysiology is weight gain, secondary to centrally mediated increases in appetite. To determine if the AAPs have detrimental metabolic effects independent of weight gain or psychiatric disease, we administered olanzapine, aripiprazole, or placebo for 9 days to healthy subjects (n = 10, each group) under controlled in-patient conditions while maintaining activity levels. Prior to and after the interventions, we conducted a meal challenge and a euglycemic-hyperinsulinemic clamp to evaluate insulin sensitivity and glucose disposal. We found that olanzapine, an AAP highly associated with weight gain, causes significant elevations in postprandial insulin, glucagon-like peptide 1 (GLP-1), and glucagon coincident with insulin resistance compared with placebo. Aripiprazole, an AAP considered metabolically sparing, induces insulin resistance but has no effect on postprandial hormones. Importantly, the metabolic changes occur in the absence of weight gain, increases in food intake and hunger, or psychiatric disease, suggesting that AAPs exert direct effects on tissues independent of mechanisms regulating eating behavior.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db13-0430

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Body weight, activity levels, hunger, and food intake after short-term administration of olanzapine, aripiprazole, or placebo. Body weight of subjects on the first (pre) and last day of the study (post) after 9 days of either olanzapine (A), aripiprazole (B) or placebo (C). D: Activity level of each group measured by the average number of steps taken during 5 days of monitoring in the free living state (solid bar) and during the 12 inpatient days (hatched bar). E: Sum of the numerical score of the hunger ratings taken over the course of each day throughout the inpatient period for each intervention arm: olanzapine (solid line, solid square), aripiprazole (dashed line, solid circle), or placebo (dotted line, solid triangle). Number of hunger ratings administered was lower on test days (days 1–3 and 10–12), hence lower mean scores. F: Mean kilocalorie intake as measured ad libitum on day 2 prior to administration of drug (solid bar) and on day 11, the 8th day of drug administration (hatched bar). No significant differences were found on any of the variables illustrated in these figures. Values are means ± SEM, n = 10 each study arm.
FIG. 1. Body weight, activity levels, hunger, and food intake after short-term administration of olanzapine, aripiprazole, or placebo. Body weight of subjects on the first (pre) and last day of the study (post) after 9 days of either olanzapine (A), aripiprazole (B) or placebo (C). D: Activity level of each group measured by the average number of steps taken during 5 days of monitoring in the free living state (solid bar) and during the 12 inpatient days (hatched bar). E: Sum of the numerical score of the hunger ratings taken over the course of each day throughout the inpatient period for each intervention arm: olanzapine (solid line, solid square), aripiprazole (dashed line, solid circle), or placebo (dotted line, solid triangle). Number of hunger ratings administered was lower on test days (days 1–3 and 10–12), hence lower mean scores. F: Mean kilocalorie intake as measured ad libitum on day 2 prior to administration of drug (solid bar) and on day 11, the 8th day of drug administration (hatched bar). No significant differences were found on any of the variables illustrated in these figures. Values are means ± SEM, n = 10 each study arm.CC BY-NC-ND · PubMed Central
FIG. 2. Postprandial plasma glucose, insulin, and C-peptide concentrations after short-term administration of olanzapine, aripiprazole, or placebo. Postprandial plasma glucose concentrations prior to (dashed line, solid square) and after administration (solid line, solid circles) of olanzapine (A), aripiprazole (B), or placebo (C). D: ΔAUC calculated from the postintervention glucose AUC minus preintervention glucose AUC. No significant differences were found. Postprandial plasma insulin concentrations prior to (dashed line, solid square) and after administration (solid line, solid circles) of olanzapine (E), aripiprazole (F), or placebo (G). ΔInsulin AUC for olanzapine was significantly greater compared with placebo (H). Postprandial plasma C-peptide concentrations prior to (dashed line, solid square) and after administration (solid line, solid circles) of olanzapine (I), aripiprazole (J), or placebo (K). ΔC-peptide AUC (L). No significant differences were found. Values are mean ± SEM. *P < 0.05.
FIG. 2. Postprandial plasma glucose, insulin, and C-peptide concentrations after short-term administration of olanzapine, aripiprazole, or placebo. Postprandial plasma glucose concentrations prior to (dashed line, solid square) and after administration (solid line, solid circles) of olanzapine (A), aripiprazole (B), or placebo (C). D: ΔAUC calculated from the postintervention glucose AUC minus preintervention glucose AUC. No significant differences were found. Postprandial plasma insulin concentrations prior to (dashed line, solid square) and after administration (solid line, solid circles) of olanzapine (E), aripiprazole (F), or placebo (G). ΔInsulin AUC for olanzapine was significantly greater compared with placebo (H). Postprandial plasma C-peptide concentrations prior to (dashed line, solid square) and after administration (solid line, solid circles) of olanzapine (I), aripiprazole (J), or placebo (K). ΔC-peptide AUC (L). No significant differences were found. Values are mean ± SEM. *P < 0.05.CC BY-NC-ND · PubMed Central
FIG. 3. Postprandial plasma GLP-1, glucagon, and triglyceride concentrations after short-term administration of olanzapine, aripiprazole, or placebo. Postprandial plasma GLP-1 concentrations prior to (dashed line, solid square) and after administration (solid line, solid circles) of olanzapine (A), aripiprazole (B), or placebo (C). D: ΔGLP-1 AUC. Olanzapine significantly increased GLP-1 compared with placebo. No significant differences were found after aripiprazole or placebo administration. Postprandial plasma glucagon concentrations prior to (dashed line, solid square) and after administration (solid line, solid circles) of olanzapine (E), aripiprazole (F), or placebo (G). ΔGlucagon AUC for olanzapine was significantly greater compared with placebo (H). Triglyceride concentrations prior to (dashed line, solid square) and after administration (solid line, solid circles) of olanzapine (I), aripiprazole (J), or placebo (K). L: ΔTriglyceride AUC. No significant differences were found. Values are means ± SEM. *P < 0.05.
FIG. 3. Postprandial plasma GLP-1, glucagon, and triglyceride concentrations after short-term administration of olanzapine, aripiprazole, or placebo. Postprandial plasma GLP-1 concentrations prior to (dashed line, solid square) and after administration (solid line, solid circles) of olanzapine (A), aripiprazole (B), or placebo (C). D: ΔGLP-1 AUC. Olanzapine significantly increased GLP-1 compared with placebo. No significant differences were found after aripiprazole or placebo administration. Postprandial plasma glucagon concentrations prior to (dashed line, solid square) and after administration (solid line, solid circles) of olanzapine (E), aripiprazole (F), or placebo (G). ΔGlucagon AUC for olanzapine was significantly greater compared with placebo (H). Triglyceride concentrations prior to (dashed line, solid square) and after administration (solid line, solid circles) of olanzapine (I), aripiprazole (J), or placebo (K). L: ΔTriglyceride AUC. No significant differences were found. Values are means ± SEM. *P < 0.05.CC BY-NC-ND · PubMed Central
FIG. 4. Indices of glucose metabolism, disposal, and insulin sensitivity prior to and after short-term administration of olanzapine, aripiprazole, or placebo. Olanzapine administration had no effect on EGP during the basal period or during steady state but significantly reduced glucose disposal (Rd) (P < 0.05) and the GIR (P < 0.05) (A). Aripiprazole similarly reduced glucose disposal and the GIR (P < 0.05) (B) compared with placebo (C). The AIR to the meal was calculated as the first 10 min of insulin release. Olanzapine (D) but not aripiprazole (E) significantly increased AIRmeal compared with placebo (F). Both olanzapine and aripiprazole decreased insulin sensitivity (P < 0.05) but the DI was not significantly different after the intervention, demonstrating adequate compensation for the prevailing insulin resistance. SI was calculated as the change in glucose disposal and dividing by the change in insulin and multiplying by glucose at steady state. DI was estimated by multiplying the SI by the AIR to the meal. Values are mean ± SEM. *P < 0.05.
FIG. 4. Indices of glucose metabolism, disposal, and insulin sensitivity prior to and after short-term administration of olanzapine, aripiprazole, or placebo. Olanzapine administration had no effect on EGP during the basal period or during steady state but significantly reduced glucose disposal (Rd) (P < 0.05) and the GIR (P < 0.05) (A). Aripiprazole similarly reduced glucose disposal and the GIR (P < 0.05) (B) compared with placebo (C). The AIR to the meal was calculated as the first 10 min of insulin release. Olanzapine (D) but not aripiprazole (E) significantly increased AIRmeal compared with placebo (F). Both olanzapine and aripiprazole decreased insulin sensitivity (P < 0.05) but the DI was not significantly different after the intervention, demonstrating adequate compensation for the prevailing insulin resistance. SI was calculated as the change in glucose disposal and dividing by the change in insulin and multiplying by glucose at steady state. DI was estimated by multiplying the SI by the AIR to the meal. Values are mean ± SEM. *P < 0.05.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

Items 101–200 of 200

Metadata

Authors
Teff, K. L., Rickels, M. R., Grudziak, J., Fuller, C., Nguyen, H.-L., & Rickels, K.
Affiliations
  • Monell Chemical Senses Center (US)
  • University of Pennsylvania (US)
Corresponding author
Teff, Karen L.
Venue
Diabetes
Published
2013-08-15
Volume
62
Issue
9
Pages
3232-3240
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2126815601
Cited by
195
References
51
Citations by year
2026: 12 · 2025: 13 · 2024: 14 · 2023: 10 · 2022: 14 · 2021: 15 · 2020: 12 · 2019: 12 · 2018: 21 · 2017: 15 · 2016: 18 · 2015: 19 · 2014: 15 · 2013: 5
FWCI
13.46
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • University of Pennsylvania
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK 19525, R01DK084383, DK084383, P30DK019525)
  • National Center for Research Resources (UL1RR024134)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
atypical antipsychotics, insulin resistance, olanzapine, aripiprazole, postprandial insulin, glucagon-like peptide-1, glucagon, glucose disposal, insulin sensitivity, metabolic side effects, weight gain, appetite, hyperinsulinemic-euglycemic clamp, meal challenge
MeSH terms
Aripiprazole, Olanzapine, Adult, Mental Disorders, Benzodiazepines, Eating, Female, Humans, Insulin Resistance, Male, Piperazines, Antipsychotic Agents, Quinolones, Weight Gain, Postprandial Period, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.